These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 9293792

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Recurrent carcinoid tumor and 18F-DOPA PET].
    Cavet M, Tenenbaum F, Hignette C, Modis C, Richard B, Faraggi M, Dousset B.
    Gastroenterol Clin Biol; 2010 Mar; 34(3):213-7. PubMed ID: 19864098
    [Abstract] [Full Text] [Related]

  • 25. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma.
    Gritters LS, Francis IR, Zasadny KR, Wahl RL.
    J Nucl Med; 1993 Sep; 34(9):1420-7. PubMed ID: 8355058
    [Abstract] [Full Text] [Related]

  • 26. Multimodality imaging features in a case of bronchial carcinoid including FDG PET.
    Shin V, Bhargava P, Brown J, Ames ED, Kang P.
    Med Sci Monit; 2007 Jan; 13(1):CS4-8. PubMed ID: 17179913
    [Abstract] [Full Text] [Related]

  • 27. Fluorine-18-FDG PET in Paget's disease of bone.
    Cook GJ, Maisey MN, Fogelman I.
    J Nucl Med; 1997 Sep; 38(9):1495-7. PubMed ID: 9293817
    [Abstract] [Full Text] [Related]

  • 28. Primary renal carcinoid tumor with liver metastases detected with somatostatin receptor imaging.
    Mufarrij P, Varkarakis IM, Studeman KD, Jarrett TW.
    Urology; 2005 May; 65(5):1002. PubMed ID: 15882749
    [Abstract] [Full Text] [Related]

  • 29. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET.
    Adler LP, Faulhaber PF, Schnur KC, Al-Kasi NL, Shenk RR.
    Radiology; 1997 May; 203(2):323-7. PubMed ID: 9114082
    [Abstract] [Full Text] [Related]

  • 30. Imaging of a metastatic gastrointestinal carcinoid by F-18-DOPA positron emission tomography.
    Hoegerle S, Schneider B, Kraft A, Moser E, Nitzsche EU.
    Nuklearmedizin; 1999 May; 38(4):127-30. PubMed ID: 10392379
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose.
    Wahl RL, Cody RL, Hutchins GD, Mudgett EE.
    Radiology; 1991 Jun; 179(3):765-70. PubMed ID: 2027989
    [Abstract] [Full Text] [Related]

  • 37. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
    Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E, Kolokythas O, Herrmann F, Reske SN.
    Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
    [Abstract] [Full Text] [Related]

  • 38. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer.
    Sazon DA, Santiago SM, Soo Hoo GW, Khonsary A, Brown C, Mandelkern M, Blahd W, Williams AJ.
    Am J Respir Crit Care Med; 1996 Jan; 153(1):417-21. PubMed ID: 8542152
    [Abstract] [Full Text] [Related]

  • 39. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
    Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK.
    J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.